Evidence map›Paper›PMID 42609047›Full record

ReviewEuropean journal of immunology2026

Endothelial Atypical Receptors for Chemoattractants in Lung Immune Surveillance.

Mattia Laffranchi, Eleonora Bonanni, Francesca Sozio, Miriam Turchetti, Giuseppe Sciumè, Marcus Thelen, Annalisa Del Prete, Raffaella Bonecchi, Silvano Sozzani

Abstract readReview
In one paragraph

Review in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mattia LaffranchiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Eleonora BonanniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Francesca SozioDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Miriam TurchettiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giuseppe SciumèDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Marcus ThelenInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
Annalisa Del PreteDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Raffaella BonecchiDepartment of Immunology, IRCCS Humanitas Research Hospital, Milan, Italy.
Silvano SozzaniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Funding

Italian Association for Cancer Research (AIRC) IG-27176 (to R.B)Italian Association for Cancer Research (AIRC) IG-29244 (to S.S)Italian Ministry of University and Research-PRIN 20228KZKE3 (to R.B.and S.S.)
6 · The paper itself

Abstract

Chemokines and their receptors play a pivotal role in the initiation and regulation of inflammation through the orchestration of leukocyte extravasation and directed migration toward sites of tissue injury. Tight control of chemokine gradients within tissues is essential to ensure that inflammatory responses remain transient and properly resolved. When this regulatory mechanism fails, dysregulated chemokine signaling can contribute to the development of chronic inflammation. Atypical receptors for chemoattractants comprise atypical chemokine receptors (ACKRs) and the chemerin-presenting receptor CCRL2. ACKRs perform specialized functions enabling the fine-tuning of chemokine gradients, primarily through the scavenging, sequestration, or redistribution of chemokines. By regulating their spatial and temporal availability, ACKRs play a key role in limiting excessive leukocyte recruitment and promoting inflammation resolution. The lungs are in a dynamic equilibrium between immune activation and homeostasis. Rapid and tightly regulated immune cell recruitment is essential for effective host defense while preventing tissue damage. In this context, ACKRs expressed by specialized lung endothelial cells are emerging as critical regulators of leukocyte trafficking and inflammatory resolution. Given the paucity of studies in this area, this review summarizes current knowledge of ACKRs and CCRL2 in lung immune surveillance and discusses their potential as therapeutic targets in lung diseases.

Indexed as

Chemotactic FactorsEndothelial CellsImmunologic SurveillanceLungReceptors, CCRReceptors, ChemokineAnimalsChemokinesHumansInflammationLeukocytesSignal TransductionCCRL2 protein, humanChemokinesChemotactic FactorsReceptors, CCRReceptors, Chemokinecell migrationchemoattractant receptorschemokinechemokine receptorendotheliumimmune systemimmunologyinflammationlunglung cancer

Identifiers

PMID42609047
PMCPMC13482114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.